Stay updated on Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer Clinical Trial page.

Latest updates to the Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoNo Change Detected
- Check17 days agoChange DetectedAdded a new entry for Thyroid gland undifferentiated (anaplastic) carcinoma and a Genetic and Rare Diseases Information Center resources reference.SummaryDifference0.2%

- Check24 days agoChange DetectedSite revision updated from v3.4.3 to v3.5.0 (v3.5.0 added, v3.4.3 removed).SummaryDifference0.1%

- Check31 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check60 days agoChange DetectedRevision updated from v3.4.1 to v3.4.2 with no visible changes to page content or functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check67 days agoChange DetectedRevision: v3.4.1 has been added and Revision: v3.4.0 has been removed.SummaryDifference0.1%

- Check75 days agoChange DetectedThe page now shows a glossary and includes a new 'Last Update Submitted that Met QC Criteria' field, along with a 'No FEAR Act Data' notice and an updated site revision 'Revision: v3.4.0'. Previously displayed items 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and 'Revision: v3.3.4' have been removed; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer Clinical Trial page.